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14. Characterization of erythromycin resistance in streptococcus pneumoniae in 
a defined suburban area 
I? IANNINI, L. OVITTORE AND L. Ross 
Departments of Medicine and Laboratory Medicine, Danbury Hospital, Danbury, CT, US. A. 
The incidence of penicillin resistant Streptococcus pneumoniae (PRSP) has been increasing in the United States. 
Approximately 50% are also resistant to erythromycin (ERSP). To determine the dynamics of ERSP in our single hospital, 
suburban community, we compared the percentage of resistant isolates found in 1998 and 1999 to the years 1994 through 
1997. Erythromycin non-susceptable S. pneumoniae (ENSSP) were defined as the total of all isolates that were resistant or 
intermediately resistant by NCCLS breakpoints, and were tested for cross resistance to penicillin g (PCN), ceftriaxone (CT), 
and levofloxacin (LEVO). Standard broth microdilution methodology was employed to establish minimal inhibitory 
concentrations (MIC’s). 
ERSP accounted for 15% and ENSSP for 20.4% of strains isolated in 1998-99. High level resistance (>16 mg/ml) was found 
in 46% of ERSP, but only 6.8% of all isolates. Isolates collected from 1994-1997 had only 7% ERSP and no high level 
resistance. 42 isolates collected between 1994 and 1999 that were ENSSP (of which 30 were ERSP) were tested for cross 
resistance. The ERSP strains were resistant to PCN 13%, CT 7% and LEVO 0% and for the total of all ENSSP strains to 60%, 
47% and 0% respectively. Erythromycin intermediately resistant strains were not cross resistant to the other antibiotics but 
were also intermediately susceptible to PCN 33%, CT and LEVO 17%. Overall non-susceptibility for the ENSSP strains was 
PCN 52%, CT and LEVO 5%. 
The incidence of ERSP and ENSSP in our community has increased dramatically in the past two years. Cross reistance is 
greatest to PCN, followed by CT and LEVO. High level erythromycin resistance is a now a serious problem in selecting 
empiric antibiotic therapy for respiratory tract infections in our area. 
15. Prevalence of the synobronchial syndrome among school children with sinusitis 
S. PLJASKK KAMENOV, M. FILIPOVIC* AND B. KAMENOV** 
Health Center, *Institute of Pulmonary Diseases, **University Paediatric Hospital, Nis, Yugoslavia 
Aim: to evaluate prevalence of synobronchial syndrome (SBSy) among school children ill with sinusitis. 
Methods; 100 school children ill with sinusitis age 7-18 years were randomly selected. The questionnaires concerning history 
of signs of sinusitis and chronic respiratory disease were filled in. Diagnoses were confirmed by lung function tests and x-ray 
examination. Criteria used to diagnose SBSy were: evidence of sinusitis, chronic respiratory disease and relationship between 
sinusitis and chronic respiratory disease exacerbation. 
Results: 65 (65%) patients with clinical evidence of chronic respiratory disease and sinusitis were found. 18 (27%) had 
obstructive, 47 (72%) non obstructive lung disease. Relationship between sinusitis and chronic respiratory disease exacerbation 
was seen in 37 (56%) examined school children. 39 (60%) school children were diagnosed as having SBSy. Exacerbation of 
chronic respiratory disease followed exacerbation of sinusitis in 2kO.6 and 5kO.4 days (P<O.O5), obstructive and non- 
obstructive lung disease. 
Conclusions: Prevalence rate of SBSy among school children ill with chronic sinusitis is 56%. Obstructive lung disease 
exacerbates earlier than non-obstructive following chronic sinusitis exacerbations 
16. The role of methylprednisolone in the treatment of pneumonia in school children 
S. PLJASKK KAMENOV, M. FILIPOVIC* AND B. KAMENOV** 
Health Center, “Institute of Pulmonary Diseases, **University Paediatric Hospital, Nis, Yugoslavia 
Aim: to establish the clinical usefulness of methylprednisolone treatment of severe pneumonia (SP) since the role of 
glucocorticoids in the management of pneumonia in school children remains controversial. 
Methods: the study included 35 cases of SP, that were admitted to our Health Center during the period February 1998 to 
February 1999. All the patients were treated with the second and third generation cephalosporin and erythromycin. One 
group of 20 patients (group A) was not treated with steroids, while the second group of 15 patients (group B) received 
1 mg/kg/day methylprednisolon. The groups were matched by age, sex, disease severity and clinical presentation. 
Results: no significant difference was noticed in: leukocyte count, percentage of lymphocytes, red blood cell sedimentation 
rate, hyperglycaemia, hypokalemia and renal dysfunction. Significantly better clinical improvement (reduced fever, chills, signs 
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of respiratory distress and improvement of roentgenographic changes) was seen in group B. There were no side effects after 
methylprednisolon treatment. 
Conclusion: the clinical efficiency of treatment with methylprednisolon may be considered established in the treatment of 
severe pneumonia. 
17. Chlamyda pneumoniae infection in COPD patients with acute exacerbation 
D. KARNAK*,S.BENGISLJN**,S.BEDERANDO.KAYACAN* 
Ankara University Medical Faculty, “Department of Chest Diseases and Tuberculosis, 
**Laboratory of Bacteriology, 06100 Cebeci-Ankaral, Turkey 
Our aim was to investigate the possible association of Chlamydia pneumoniae (Cpn) infection with acute exacerbation in 
COPD patients. For this purpose, 38 COPD patients who had acute exacerbations of respiratory conditions and 17 healthy 
smokers without respiratory disease were enrolled in the study, as study and control groups respectively. Nasopharyngeal 
swabs and paired serum samples were obtained from all subjects for antibody testing of Cpn. Sputum cultures of COPD 
patients were also performed. No pathogenic bacteria were isolated from nasopharyngeal swabs in any subject. IgM antibody 
which is a serologic evidence of recent Cpn infection was observed in 15 COPD patients (39%) and one control subject (0.5%). 
The prevalence of Cpn IgG antibodies were significantly higher in COPD patients than in control subjects (PcO.05). 
Prevalence of IgA antibodies did not show difference between two groups (P>O.O5). Microbiologic culture of the sputa 
yielded potentially pathogenic microorganisms in 23 of 38 COPD patients (60%). S. pneumoniae (4%) H. influenza (4%), 
a-hemolytic streptococcus (35%), Niesseria spp (30%), Candida spp (9%) S. aureus (4%), l? aeruginosa (4%) were isolated. 
Although a high prevalence of IgG antibodies against Cpn was detected in COPD patients, Cpn was the sole causative agent 
in only 4 patients (10%). We conclude that most patients with COPD are chronically infected with Cpn and it may either be 
the only causative agent or a co-agent in the acute exacerbation. 
18. Clinical outcome of community-acquired pneumonia (CAP) in hospitalized 
patients. Experience from the central Moravia 
V. KOLEK, H. FOJT~, M. KOLARAND I. VAGNEROVA 
Dept. of Pulmonary med. and Microbiology, University Hospital, Olomouc, Czech Republic 
Present work evaluates 101 consecutive cases of CAP from the central Moravia hospitalized in the pulmonary department 
from 1996 to 1999. Before hospitalization 63 patients were treated with one or more antibiotics: penicillins ( 38%), macrolides 
(28%), cotrimoxazol (9%) and cephalosporins (2%). Risk factors were as follows: infiltration greater than one lobe (57 pts), 
age older than 60 (52 pts), pleural reaction (44), considerable changes in vital signs (30) polymorbidity (16), hemoptysis (lo), 
mental alteration (10) and cavitation on the chest X-ray in 8 pts. There was hypoxemia in 84 pts, hypercapnia in 13, 
leucocytosis above 20 000 in 8 and bacteremia in 6 pts. The mean length of symptom duration was 8.4 days, the mean length 
of stay in hospital was 18.9 days. Recognized pathogens were: C. pneumoniae (19), H. infuenzae (16), Enterobact. sp. (15) 
M. pneumoniae (1 l), S. pneumoniae (lo), K. pneumoniae (9). In the oral treatment fluorochinolons (23.1%), penicillins (22.2%), 
tetracyclines (21.9%) antimycotics (12.1%), cephalosporins (11.6%) and macrolides (4%) were used. Parenteral treatment was 
realized by penicillins (45.3%), cephalosporins (33.7%) and aminoglycosides (14.5%). There were 9 cases of empyema, 4 cases 
of lung abscess, 6 patients were referred to ICU and 3 died. In the follow up 37 patients suffered from functional respiratory 
impairment. 
19. Moxifloxacin susceptibility program (MSP): national and regional in vitro 
susceptibility of common respiratory tract pathogens 
S.KOWALSKY,R.PRYKA, J. HARRIS,K.GRAVELLE,B.PAINTERANDTHE MSP STUDYGROUP 
The Moxifloxacin Susceptibility Program (MSP) was initiated to test the susceptibilities of common respiratory tract 
pathogens against commonly prescribed antimicrobials including the new 8-methoxyfluoroquinolone, moxifloxacin. The 
comparative agents tested were trovafloxacin, levofloxacin, penicillin, cefuroxime, amoxicillin/clavulanate, azithromycin, and 
trimethoprim-sulfamethoxazole. Fresh and/or frozen clinical isolates were collected from July 1998-November 1999. 
Organisms included Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus injluenzae, Moraxella catarrhalis, and 
Klebsiella pneumoniae. The data collected included clinical source (blood/sputum) of the isolate, clinical location (community 
